Fundamental Research Division
The DRF at the CEA assemble approximately 6,000 scientists since January 2016.
Scientific result | Health ＆ life sciences | Virus | Chikungunya
Easier to produce and administer, the highest potential vaccine relies on the attenuated virus. The scientists will now try to optimize its protocol of use, by reducing the injected doses to find the best dose/effectiveness balance to ensure reinforced safety. This work therefore provides a solid basis for the clinical development of a vaccine that would be effective against Chikungunya in the long term.
 Integration of Chikungunya RESearch
 MVA (non-pathogenic, Modified Vaccinia virus Ankara)
Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus | JCI Insight
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.